Program
bemdaneprocel
Also written as “MSK-DA01”.
Its studies are mostly in Parkinson Disease, led by Bayer.
Furthest: phase 3, since Apr 7, 20252 company-led studies, 1 open or runningNext primary completion: Oct 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 21 open or running | phase 3since Apr 7, 2025 | Mar 12, 2021 | Oct 2028phase 3 · NCT06944522 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 12, 2021First study: phase 1 study in Advanced Parkinson's DiseaseFirst studyNCT04802733 · 12 enrolled · United States, Canada
- Apr 7, 2025Phase 3 study in Parkinson DiseaseNCT06944522 · 102 planned · United States, Australia, Canada
- Oct 30, 2026Primary completion moved from 2027-03 to 2028-10Date moved laterphase 3 · +19 months · NCT06944522
Ahead
- Oct 2028Primary completion: phase 3 study in Parkinson DiseaseNCT06944522
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06944522Parkinson Disease · United States, Australia, Canada | 3 | Recruiting | Oct 2028 | 102 |
| NCT04802733Advanced Parkinson's Disease · United States, Canada | 1 | Completed | May 18, 2023 | 12 |
How it is read
Names in the registry
- “bemdaneprocel”, 1 entry
- “MSK-DA01”, 1 entry
Conditions, from the studies’ own filings
- Parkinson Disease, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.